CoChat

The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use

Open access
Large, Charles H., Sokal, David M., Nehlig, Astrid, Gunthorpe, Martin J., Sankar, Raman, Crean, Christopher S., VanLandingham, Kevan E., White, H. Steve · 2012 · Epilepsia
Cited by 73

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Summary: Retigabine [RTG (international nonproprietary name); ezogabine (EZG; U.S. adopted name)] is a first‐in‐class antiepileptic drug (AED) that reduces neuronal excitability by enhancing the activity of KCNQ (K v 7) potassium (K+) channels. RTG/EZG has recently been approved by the European Medicines Agency and the U.S. Food and Drug Administration as adjunctive therapy in adults with partial‐onset seizures. In this review we discuss the activity that RTG/EZG has demonstrated across a broad spectrum of in vitro/in vivo animal models of seizures, including generalized tonic–clonic, primary generalized (absence), and partial seizures, in addition to the compound’s ability to resist and block the occurrence of seizures induced by a range of stimuli across different regions of the brain. The potency of RTG/EZG in models refractory to several conventional AEDs and the work done to assess antiepileptogenesis and neuroprotection are discussed. Studies that have evaluated the central nervous system side effects of RTG/EZG in animals are reviewed in order to compare these effects with adverse events observed in patients with epilepsy. Based on its demonstrated effect in a number of animal epilepsy models, the synergistic and additive activity of RTG/EZG with other AEDs supports its potential use in therapeutic combinations for different seizure types. The distinct mechanism of action of RTG/EZG from those of currently available AEDs, along with its broad preclinical activity, underscores the key role of KCNQ (K v 7) K+ channels in neuronal excitability, and further supports the potential efficacy of this unique molecule in the treatment of epilepsy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1528-1167.2011.03364.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 73

Metadata

Authors
Large, C. H., Sokal, D. M., Nehlig, A., Gunthorpe, M. J., Sankar, R., Crean, C. S., VanLandingham, K. E., & White, H. S.
Venue
Epilepsia
Publisher
Wiley
Published
2012-01-05
Volume
53
Issue
3
Pages
425-436
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W1596694562
Cited by
73
References
3
FWCI
7.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use. https://app.cochat.ai/papers/10.1111/j.1528-1167.2011.03364.x
The paper
Large, C. H., Sokal, D. M., Nehlig, A., Gunthorpe, M. J., Sankar, R., Crean, C. S., VanLandingham, K. E., & White, H. S. (2012). The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use. Epilepsia. https://doi.org/10.1111/j.1528-1167.2011.03364.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.